Overview: CD38 Flow Cytometry TestIntroduction: The CD38 Flow Cytometry Test detects CD38 markers to diagnose multiple myeloma or lymphoma, causing bone pain or fatigue. Aligned with 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected multiple myeloma or lymphoma.
Other Names: CD38 Flow Assay, ADP-Ribosyl Cyclase Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: CD38 testing began in the 1990s with myeloma research. Flow cytometry emerged in the 2000s, improving accuracy for marker detection.
Purpose: Diagnoses multiple myeloma or lymphoma, guides treatment, and monitors CD38 markers in patients with bone pain or fatigue.
Test Parameters: 1. CD38
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like bone pain or fatigue, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document bone pain, fatigue, or history of multiple myeloma/lymphoma. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect CD38 markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express CD38.
Clinical Significance: Positive CD38 expression suggests multiple myeloma or lymphoma, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, serum protein electrophoresis, or imaging to confirm multiple myeloma/lymphoma.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Myeloma Guidelines, 2023; Blood, Rajkumar SV, 2022.
